Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Study in Subjects With Relapsing Remitting Multiple Sclerosis to Evaluate the Tolerability of ALKS 8700 and Dimethyl Fumarate

NCT03093324 is registered in ClinicalTrials.gov with Biogen as lead sponsor.

NCT NCT03093324
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03093324 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Study in Subjects With Relapsing Remitting Multiple Sclerosis to Evaluate the Tolerability of ALKS 8700 and Dimethyl Fumarate
Lead sponsor
Biogen
Phase
Phase 3
Overall status
Completed
Start date
March 15, 2017
Completion date
June 27, 2019
Enrollment
506 (actual)
Sites
67

Conditions

As the registry lists them; a condition with its own page is linked.

relapsing remitting multiple sclerosis